Placenta-derived stem cell therapy may benefit patients with Crohn’s disease

The successes for adult, cord blood, and placental-derived stem cells just keep piling up. Now comes an AP report saying, “Celgene Corporation … reported a successful safety trial of a placenta-derived stem cell therapy as a treatment for Crohn’s disease.”

During the trial, “12 patients with moderate to severe Crohn’s disease,” who had been previously treated unsuccessfully, “were given two infusions of Celgene’s PDA-001 at one week apart, at one of two doses.”

According to Celgene, patients who received a lower-dose of PDA-001 appeared to benefit from the treatment and clinical remission was noted in four participants, Reuters reported.

Such findings were considered so encouraging that the firm has decided to test the therapy on a broad spectrum of diseases.

What’s more, PDA-001 is unlikely to draw ire, because it is cultivated from healthy, full-term human placental tissue.

Could this be another death knell for the unwise and unethical research on stems cells taken from unborn human children? I could only hope and pray so.

This entry was posted in Bioethics and tagged , , , , , , , . Bookmark the permalink.